Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE

AACR 2023

AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor

This poster was presented at the 2023 AACR Annual Meeting. To read the full study report download the poster.